背景:抗病毒治疗可以减轻COVID-19的负担。但是利用率可能是次优的,即使在像新加坡这样的环境中,对于那些有特定医疗条件的人和老年人(≥50岁)也有全额补贴。因此,我们调查了影响意识的因素,接受,并主动要求Paxlovid。
方法:我们评估了Paxlovid的意识,在2022年8月至2022年9月通过SOCRATES队列进行的一项调查中,影响其吸收的因素。多变量逻辑回归用于调查社会人口统计,感知,以及对关键研究结果的态度。
结果:在Paxlovid调查的受访者中,54%的人知道Paxlovid。关于Paxlovid的基本细节,75%的人报告说,如果开处方,他们可能会接受服用,38%的人表示,如果他们的医生没有建议,他们会主动提出要求。与Paxlovid意识相关的因素包括40岁及以上,高等教育,引用网站作为信息来源,对医疗保健提供者(aOR:1.65,95%CI1.26-2.15)和政府沟通(aOR:0.69,95%CI0.55-0.86)的更大信任,和更高的COVID-19感染风险(aOR:1.25,95%CI1.10-1.42)。与接受Paxlovid相关的因素包括男性,引用对医疗保健提供者的信任(aOR:1.49,95%CI1.11-1.99)和政府沟通(aOR:1.38,95%CI1.09-1.76),和更高的COVID-19严重程度(aOR:1.23,95%CI1.07-1.42)。与主动请求Paxlovid相关的因素包括男性,患有预先存在的糖尿病和更高的COVID-19严重程度(aOR:1.24,95%CI1.09-1.40)。受访者可能不服用Paxlovid的最常见原因是对副作用的担忧(64%)。对成本的担忧(29%),和认为COVID-19是轻度的(25%)。
结论:如果给他们开处方,我们的大多数受访者会服用Paxlovid,但是只有一小部分人会主动要求这样做。可能影响摄取的关键因素是COVID-19威胁感知,对医疗保健和政府的信任,以及对药物副作用和成本的看法。
BACKGROUND: Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years). We hence investigated the factors affecting awareness, acceptance, and initiative to request Paxlovid.
METHODS: We assessed the Paxlovid awareness, factors impacting its uptake in a survey conducted from August 2022 to September 2022 through the SOCRATES cohort. Multivariable logistic regression was used to investigate associations between sociodemographics, perceptions, and attitudes with the key study outcomes.
RESULTS: Among respondents to the Paxlovid survey, 54% were aware of Paxlovid. On being provided essential details about Paxlovid, 75% reported they would likely be receptive to taking it if prescribed, and 38% indicated the initiative to request for it if it was not suggested by their doctors. Factors associated with awareness of Paxlovid include aged 40 years old and above, higher education, citing websites as an information source, greater trust in healthcare providers (aOR: 1.65, 95% CI 1.26 - 2.15) and government communications (aOR: 0.69, 95% CI 0.55 - 0.86), and higher perceived risk of COVID-19 infection (aOR: 1.25, 95% CI 1.10 - 1.42). Factors associated with acceptance to take Paxlovid include male gender, citing trust in healthcare providers (aOR: 1.49, 95% CI 1.11 - 1.99) and government communications (aOR: 1.38, 95% CI 1.09 - 1.76), and higher perceived severity of COVID-19 (aOR: 1.23, 95% CI 1.07 - 1.42). Factors associated with initiative to request Paxlovid include male gender, having pre-existing diabetes and higher perceived severity of COVID-19 (aOR: 1.24, 95% CI 1.09 - 1.40). The most common reasons for why respondents might not take Paxlovid were concerns about side effects (64%), concerns about costs (29%), and the perception that COVID-19 is a mild (25%).
CONCLUSIONS: The majority of our respondents would take Paxlovid if it was prescribed to them, but a much smaller proportion would have the initiative to request for this. Key factors that may influence uptake are COVID-19 threat perceptions, trust in healthcare and government, and perceptions of the drug\'s side effects and cost.